Abstract
Increasing evidence points to the possible risks of delayed effects upon prenatal exposure to chemicals; the evaluation of such effects may pose serious problems to clinicians, epidemiologists and toxicologists. In fact, several systems (e.g., nervous, excretory) show important developmental processes well after the organogenetic period, up to the postnatal phase; accordingly, these are also expected to be sensitive targets of developmental toxicants, resulting in impairment of the function and/or functional reserve. This review describes the effects of several groups of drugs on the functional maturation and histogenesis of the kidney (e.g., aminoglycosides, angiotensin-converting enzyme inhibitors, indomethacin) and brain (e.g., anticonvulsivants, antiretroviral compounds, benzodiazepines) upon exposure in utero of humans and laboratory animals. The available data stress the importance for risk assessment of an adequate knowledge of both developmental biology and mechanisms of toxicity. The design of developmental toxicity studies should allow an evaluation of targets most relevant for a given drug (or group of drugs); moreover, the analysis of functional development should receive the due attention within the safety assessment of chemicals.
Keywords: aminoglycosides angiotensin-converting enzyme inhibitors, Aminoglycosides, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), dexamethasone, Glucocorticoids, Diuretic Agents, acetazolamide, amiloride, chlorothiazide
Current Pharmaceutical Design
Title: Delayed Developmental Effects Following Prenatal Exposure to Drugs
Volume: 7 Issue: 9
Author(s): Alberto Mantovani and Gemma Calamandrei
Affiliation:
Keywords: aminoglycosides angiotensin-converting enzyme inhibitors, Aminoglycosides, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), dexamethasone, Glucocorticoids, Diuretic Agents, acetazolamide, amiloride, chlorothiazide
Abstract: Increasing evidence points to the possible risks of delayed effects upon prenatal exposure to chemicals; the evaluation of such effects may pose serious problems to clinicians, epidemiologists and toxicologists. In fact, several systems (e.g., nervous, excretory) show important developmental processes well after the organogenetic period, up to the postnatal phase; accordingly, these are also expected to be sensitive targets of developmental toxicants, resulting in impairment of the function and/or functional reserve. This review describes the effects of several groups of drugs on the functional maturation and histogenesis of the kidney (e.g., aminoglycosides, angiotensin-converting enzyme inhibitors, indomethacin) and brain (e.g., anticonvulsivants, antiretroviral compounds, benzodiazepines) upon exposure in utero of humans and laboratory animals. The available data stress the importance for risk assessment of an adequate knowledge of both developmental biology and mechanisms of toxicity. The design of developmental toxicity studies should allow an evaluation of targets most relevant for a given drug (or group of drugs); moreover, the analysis of functional development should receive the due attention within the safety assessment of chemicals.
Export Options
About this article
Cite this article as:
Mantovani Alberto and Calamandrei Gemma, Delayed Developmental Effects Following Prenatal Exposure to Drugs, Current Pharmaceutical Design 2001; 7 (9) . https://dx.doi.org/10.2174/1381612013397717
DOI https://dx.doi.org/10.2174/1381612013397717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adjuvant and Antigen Delivery Properties of Virosomes
Current Drug Delivery Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property
Endocrine, Metabolic & Immune Disorders - Drug Targets Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology Generation of Universal Red Blood Cells: An Evaluation of Various Approaches
Recent Patents on Biomedical Engineering (Discontinued) 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry The Role of Apoptosis in Influenza Virus Pathogenesis and the Mechanisms Involved in Anti-Influenza Therapies
Current Chemical Biology <i>Achillea millefolium</i> E.Mey: Phytochemistry and Pharmacological Profile
Current Traditional Medicine Editorial [Hot Topic: Organ Involvement in the Antiphospholipid Syndrome (Guest Editors: Gerard Espinosa and Ricard Cervera)]
Current Rheumatology Reviews Flow Cytometric Analysis of Pro-inflammatory Cytokine Production in Hyperglycemic Mouse Model
Recent Patents on Food, Nutrition & Agriculture Vaccines and Vaccine Strategies Against HIV
Current Drug Targets Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research Curcumin and its Derivatives: Their Application in Neuropharmacology and Neuroscience in the 21st Century
Current Neuropharmacology Pseudomonas aeruginosa Invades Human Aortic Endothelial Cells and Induces Cell Damage in vitro
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms of and Possible Treatment Strategies for Idiopathic Pulmonary Fibrosis
Current Pharmaceutical Design Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Serotonin-Dopamine Interaction as a Focus of Novel Antidepressant Drugs
Current Drug Targets Molecular Farming of Pharmaceutical Proteins Using Plant Suspension Cell and Tissue Cultures
Current Pharmaceutical Design Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Applications of Important Polysaccharides in Drug Delivery
Current Pharmaceutical Design